申请人:AbbVie Inc.
公开号:US20140051695A1
公开(公告)日:2014-02-20
The present invention relates to compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof
where in formula I the variables R
1
, R
2
, R
3
, R
4
and R
5
are as defined in the claims and where X is C—R
6
or N, Y is C—R
7
or N, where R
6
and R
7
are, inter alia, hydrogen, halogen, alkoxy, haloalkoxy and the like.
The compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
本发明涉及公式I的化合物,其N-氧化物,互变异构体,前药和药学上可接受的盐,其中在公式I中,变量R1,R2,R3,R4和R5如权利要求所定义,其中X为C-R6或N,Y为C-R7或N,其中R6和R7为氢,卤素,烷氧基,卤代烷氧基等。
公式I的化合物,其N-氧化物,互变异构体,前药和药学上可接受的盐是磷酸二酯酶10A的抑制剂,可用于制造药物,因此适用于治疗或控制神经系统疾病和精神障碍等医学疾病,改善与此类疾病相关的症状并降低此类疾病的风险。